NEW YORK, August 10, 2026, 07:02 EDT — Shares active in Nasdaq premarket; normal session begins at 09:30 EDT.
- Shares of Steakholder Foods rose 161.6% to $4.9189, with 15.87 million ADSs changing hands before the market opened.
- The price was 146% higher than the exercise price for 3.5 million recently issued warrants.
- If fully exercised, the warrants could yield $7 million, pending shareholder approval.
Steakholder Foods Ltd. NASDAQ:STKH surged over 100% ahead of the market open on Monday, recovering from a 26.3% decline on Friday and ranking the stock among the premarket’s top gainers.
The price acts more as a trigger for funding than as an indication of valuation. It pushed 3.5 million newly issued warrants far above their $2 strike price.
The warrants have the potential to provide Steakholder with an additional $7 million in gross proceeds. However, shareholders must first approve an increase in authorized ordinary shares before the warrants can be exercised. While the rally boosts the economic motivation to exercise, it does not generate immediate cash.
| Trading measure | Latest reading | Investor comparison |
|---|---|---|
| Monday premarket price | $4.9189 | Rose 161.64% from Friday |
| Premarket volume | 15.87 million | Equal to 13.3 times the 65-day daily average |
| Friday close | $1.88 | Dropped 26.27% in the session |
| Friday regular-session volume | 223,780 | Amounts to only 19% of the 65-day average |
| Jul. 31 to Aug. 7 | $2.40 to $1.88 | Fell 21.7% from close to close |
FactSet-powered feeds supply the market and historical data. Reported figures are used to determine ratios.
After the August 3 financing update, the monitored feeds showed no issuer filing. No new company statement had surfaced by the time of the dateline. This indicates that trading dynamics likely contributed to Monday’s activity.
Last week saw significant fluctuations. Steakholder rose 15.8% on Monday before falling over the next three sessions. A drop on Friday left the stock down 21.7% for the week.
| Prior session | Close | Change on day | Volume |
|---|---|---|---|
| Monday, Aug. 3 | $2.78 | +15.83% | 7.52 million |
| Tuesday, Aug. 4 | $2.90 | +4.32% | 441,240 |
| Wednesday, Aug. 5 | $2.57 | -11.38% | 192,590 |
| Thursday, Aug. 6 | $2.55 | -0.78% | 439,400 |
| Friday, Aug. 7 | $1.88 | -26.27% | 223,780 |
(Source: )
The financing was finalized on August 3. The deal comprised 1.75 million pre-funded warrants, along with two additional warrant series. Each standard series corresponds to another 1.75 million ADSs.
This results in a significant possible supply surplus. The two $2 series are equivalent to 5.9 times the 591,689 ADSs FactSet lists as outstanding. All investor warrant equivalents total roughly 8.9 times that number. The share count may not reflect the latest exercises.
| Instrument | ADS equivalents | Exercise price | Status and dilution comparison |
|---|---|---|---|
| Pre-funded warrants | 1.75 million | $0.01 | Can be exercised right away; equals 3.0 times current ADSs |
| Series E warrants | 1.75 million | $2.00 | Needs shareholder approval |
| Series F warrants | 1.75 million | $2.00 | Needs shareholder approval |
| Series E and F combined | 3.50 million | $2.00 | Equivalent to 5.9 times current ADSs |
| Initial placement-agent warrants | 122,500 | $2.50 | Represents additional possible dilution |
Series E will expire 18 months from the most recent registration and approval date. Series F is valid for five years under identical terms. Cash exercises additionally result in extra placement-agent fees and warrants.
This is the main trade-off for investors. If the price stays above $2, Steakholder gains better access to financing. However, those same instruments could result in a significant increase in its ADS count.
Steakholder reported operational cash outflows of $6.745 million in 2025, representing a decrease of 20.3% compared to the previous year. The company ended the year with $3.087 million in cash, and did not record any revenue for 2025.
| Preliminary funding scenario | Gross proceeds | Months of 2025 operational cash usage | Main requirement |
|---|---|---|---|
| Initial placement | $3.5 million | 6.2 months | Based on full exercise of pre-funded warrants |
| Series E and F warrants | $7.0 million | 12.5 months | Full cash exercise following shareholder authorization |
| Total maximum proceeds | $10.5 million | 18.7 months | All warrants exercised for cash |
The forecasts keep 2025 operating cash consumption the same. Placement fees, additional expenses, and shifts in expenditures are not included. These figures do not represent company guidance.
The annual report indicated current cash levels would not be adequate for the next 12 months. It also expressed significant uncertainty concerning ongoing operations. The recent capital injection eases some of that strain, though only a portion is accessible immediately.
Commercial evidence is still sparse. Steakholder’s debut Perfecta delivery arrived in the United States in July. The product was initially set to be distributed to numerous Northeastern locations via KeHE Distributors.
Chief Executive Arik Kaufman described Perfecta as “a real game changer.” Product revenue reporting has not yet verified this statement. Management earlier outlined plans for regional expansion over the coming third and fourth quarters. SEC
Analyst data is notably limited. Existing databases present conflicting information, and no identified sell-side price target could be independently confirmed.
| Analyst-data provider | Current recommendation reading | Ratings counted | Important limitation |
|---|---|---|---|
| FactSet via WSJ | Buy | 1 | Target shown may be affected by company actions |
| MarketBeat/Benzinga | Sell | 1 | Weiss Ratings E+ assigned May 26 |
| Barchart/Zacks | Strong Buy | 1 | Analyst name unavailable |
| TipRanks | No human consensus | 0 | No analyst coverage in past three months |
The data points lack a reliable consensus. Limited coverage and ongoing changes in the ADS ratio make comparisons difficult. On July 27, Steakholder carried out a one-for-three reverse adjustment of its ADSs.
The coming week features a single firm filing deadline. Steakholder has committed to submit a warrant-resale registration statement by August 15. It is required to make every reasonable effort to obtain effectiveness within 45 days, extending to 75 days if subject to SEC review.
Investors are also awaiting details on when the shareholder vote will take place. If approved, the Series E and F warrants would become exercisable. Merely filing a registration would not indicate customer demand or the presence of recurring revenue.
Risks: Premarket increases may quickly turn negative, especially for stocks with low capitalization. Warrants could be exercised without cash or remain unexercised. Ongoing dilution, operating deficits, registration setbacks, and unpredictable Perfecta sales continue to be significant concerns.



